Alconil

• CAT Number: I021744
• CAS Number: 97677-19-5
• Molecular Formula: C15H9FN2O2
• Molecular Weight: 268.25
• Purity: 98%
• Synonyms: Alconil; Al 1567; Al-1567; Al1567
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: Spiro(9H-fluorene-9,4'-imidazolidine)-2',5'-dione, 2-fluoro-
• InChI: InChI=1S/C15H9FN2O2/c16-8-5-6-10-9-3-1-2-4-11(9)15(12(10)7-8)13(19)17-14(20)18-15/h1-7H,(H2,17,18,19,20)
• InChIKey: JRGBXEJDIMXJAP-UHFFFAOYSA-N
• SMILES: O=C1NC2(C(N1)=O)C3=C(C4=C2C=CC=C4)C=CC(F)=C3

Alconil is a biochemical.

Reference

1: Cartault F, Munier P, Jacquemont ML, Vellayoudom J, Doray B, Payet C, Randrianaivo H, Laville JM, Munnich A, Cormier-Daire V. Expanding the clinical spectrum of B4GALT7 deficiency: homozygous p.R270C mutation with founder effect causes Larsen of Reunion Island syndrome. Eur J Hum Genet. 2015 Jan;23(1):49-53. doi: 10.1038/ejhg.2014.60. Epub 2014 Apr 23. PubMed PMID: 24755949; PubMed Central PMCID: PMC4266744.
2: Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimesters of pregnancy on the estimation of individual patient-specific risks and detection rates for Down’s syndrome. Ann Clin Biochem. 2003 May;40(Pt 3):219-31. PubMed PMID: 12803832.
3: Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ. 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 2000 Jun 23;868(2):191-201. PubMed PMID: 10854571.
4: Brazzell RK, Park YH, Wooldridge CB, McCue B, Barker R, Couch R, York B. Interspecies comparison of the pharmacokinetics of aldose reductase inhibitors. Drug Metab Dispos. 1990 Jul-Aug;18(4):435-40. PubMed PMID: 1976064.
5: Park YH, McCue BA, Dobbs RE, York BM, Brazzell RK. High-performance liquid chromatographic assay of the aldose reductase inhibitor spiro-(2-fluoro-9H-fluorene-9,4′-imidazolidine)-2′,5′-dione (AL01567) in plasma and urine and its pharmacokinetics in humans. J Pharm Sci. 1988 Jul;77(7):591-5. PubMed PMID: 3139862.
6: Lou MF, Dickerson JE Jr, Garadi R, York BM Jr. Glutathione depletion in the lens of galactosemic and diabetic rats. Exp Eye Res. 1988 Apr;46(4):517-30. PubMed PMID: 3133235.
7: Thomas DM, Mahendroo PP, Lou MF. Dynamic phosphorus-31 NMR study of sugar cataract and its prevention in rat lenses with aldose reductase inhibitors. Exp Eye Res. 1988 Jan;46(1):37-47. PubMed PMID: 3125056.
8: Griffin BW, McNatt LG, Chandler ML, York BM. Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats. Metabolism. 1987 May;36(5):486-90. PubMed PMID: 3106757.
9: Ohrloff C, Hockwin O, Korte I, Wegener A. [Aldose reductase inhibitor–a new way for preventing diabetic lens changes?]. Klin Monbl Augenheilkd. 1986 Nov;189(5):361-2. German. PubMed PMID: 3100860.
10: Griffin BW, McNatt LG. Characterization of the reduction of 3-acetylpyridine adenine dinucleotide phosphate by benzyl alcohol catalyzed by aldose reductase. Arch Biochem Biophys. 1986 Apr;246(1):75-81. PubMed PMID: 3083781.
11: Kador PF, Kinoshita JH, Sharpless NE. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. J Med Chem. 1985 Jul;28(7):841-9. Review. PubMed PMID: 3925146.